Diabetes Mellitus, Type 2
Conditions
Keywords
type 2 diabetes, GLP-1 receptor agonists, subtypes, phenotypes
Brief summary
The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with type 2 diabetes. The main questions it aims to answer are: * people with type 2 diabetes belonging to specific subtypes respond better (or worse) to GLP-1RA? * the beneficial effect of GLP-1RA may last longer in people with type 2 diabetes belonging to specific subtypes? * what are the clinical characteristics that better explain the efficacy and durability of GLP-1 receptor agonists in type 2 diabetes management? Clinical data from records of patients attending the diabetes outpatient clinic of our facility will be retrieved to compare the outcomes of GLP-1 receptor agonists in patients belonging to four subtypes of type 2 diabetes.
Detailed description
Patients with type 2 diabetes are all characterized by hyperglycemia, however their probability to develop micro- and micro-vascular complications. A classification of adult-onset diabetes in 5 subtypes was recently proposed: severe autoimmune diabetes (SAID - including type 1 diabetes and latent autoimmune diabetes in adults LADA), severe insulin resistant diabetes (SIRD), severe insulin deficient diabetes (SIDD), mild age related diabetes (MARD), mild obesity-related diabetes (MOD). This classification has been validated in a multiple populations of patients with recent onset diabetes (within 5 years). However, this classification requires the measurement of c-peptide/insulinemia or anti- glutamic acid decarboxylase (GAD) antibodies, limiting its applicability in everyday clinical practice. An alternative algorithm requiring easily available clinical characteristics, such as BMI, height, waist circumference, HbA1c, fasting blood glucose, lipid profile, age and age at diagnosis was recently introduced and validated. In this retrospective observational study, the calculated sample size was of 128 patients, in 4 groups, with alpha 0.05, 1-beta 0.80, effect size 0.3. The following data will be retrieved for eligible patients: age, sex, diabetes duration, age at diagnosis, antidiabetes therapy, body weight, height, waist circumference, fasting blood glucose, HbA1c, total and HDL and LDL cholesterol, triglycerides, creatinine, microalbuminuria. The algorithm available online (https://uiem.shinyapps.io/diabetes\_clusters\_app/), will be used to assign enrolled patients to the 4 subtypes of type 2 diabetes (SIDD, SIRD, MARD, MOD). If available, information regarding micro- and macro-vascular complications of diabetes will be retrieved. All data will be collected at baseline visit and every follow-up visit (the first follow-up visit should 6-12 months following prescription of a GLP-1 receptor agonist).
Interventions
DRUGGLP-1 receptor agonist
Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
Sponsors
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Italian patients with type 2 diabetes * Onset of diabetes at ≥ 50 years * Diagnosis of type 2 diabetes ≤ 5 years from enrollment * BMI ≥ 25 kg/m2 * Patients receiving a GLP-1RA prescription for the first time with at least one follow-up visit at 6-12 months from first prescription
Exclusion criteria
* Autoimmune diabetes, monogenic diabetes, secondary diabetes * History of diabetic ketoacidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes | Difference in HbA1c change from baseline will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in time to failure among SIDD, SIRD, MARD, MOD subtypes | Difference in time to failure will be assessed up to the last available visit (up to 36 months) | In patients reaching HbA1c \<7% at first follow-up visit, the difference in time to failure (defined as HbA1c equal or above 7%) |
| Difference in fasting blood glucose change from baseline (mg/dl) among SIDD, SIRD, MARD, MOD subtypes | Difference in fasting blood glucose change from baseline (mg/dl) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation) | mg/dl |
| Difference in body weight change from baseline (kg) among SIDD, SIRD, MARD, MOD subtypes | Difference in body weight change from baseline (kg) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation) | kg |
| Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes | Difference in percentage of patients reaching HbA1c below 7% will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation) | — |
Countries
Italy
Outcome results
None listed